Celadon Pharmaceuticals has confirmed that its chief financial officer (CFO), Jonathan Turner, will leave his position on the board on 27 December.

The pharmaceutical company said its board would like to “express its thanks and gratitude” to Turner for his contribution to the company and “wishes him well in his future endeavours”.

Celadon focuses on the development, production and sale of cannabis-based medicines. Its primary focus is on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

In a statement to the London Stock Exchange, Celadon said: “The company will be starting the search for Mr Turner’s successor imminently and will provide a further update when a new candidate has been appointed.”

---